Promising Publication: The Novel Schizophrenia Treatment Gaining Traction

Author(s):

Stephen Brannan, MD

Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on the phase II clinical data for KarXT, published in the New England Journal of Medicine.

Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.

Related Videos

Open Label Phase 3 Study of Brilaroxazine for Schizophrenia Shows Efficacy, Tolerability

Use of Plasma Levels of Antipsychotics: A Conversation With Jonathan M. Meyer, MD, DLFAPA

Poster at APA Annual Meeting Explores the Use of GLP-1 Agonists for Antipsychotic-Associated Metabolic Issues

Serious Mental Illness, Substance Use Disorders, and Long-Acting Injectables in the Emergency Setting

New Research on Addressing Metabolic Issues Associated With Antipsychotics at APA Annual Meeting

Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD, Shares Insights on the Latest Findings

Medications for Different Domains of Schizophrenia

Educating Patients About Cobenfy for the Treatment of Schizophrenia

Answering 3 Clinical Questions in the Wake of the Removal of the Clozapine REMS Requirement

A Clinical Challenge: Transitioning Patients to Cobenfy